एज़ेटिमाइब के इंटरैक्शन

When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (एज़ेटिमाइब लेबल, निषेध (कॉन्ट्राइंडिकेशन))

When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (एज़ेटिमाइब लेबल, निषेध (कॉन्ट्राइंडिकेशन))

When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (एज़ेटिमाइब लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Co-administration of ZETIA with fibrates other than fenofibrate is not recommended [see Adverse Reactions (6.1) ] . (एज़ेटिमाइब लेबल, दवाओं के इंटरैक्शन)

When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (एज़ेटिमाइब लेबल, निषेध (कॉन्ट्राइंडिकेशन))

When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (एज़ेटिमाइब लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Co-administration of ZETIA with fibrates other than fenofibrate is not recommended [see Adverse Reactions (6.1) ] . (एज़ेटिमाइब लेबल, दवाओं के इंटरैक्शन)

When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (एज़ेटिमाइब लेबल, निषेध (कॉन्ट्राइंडिकेशन))

When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (एज़ेटिमाइब लेबल, निषेध (कॉन्ट्राइंडिकेशन))

When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (एज़ेटिमाइब लेबल, निषेध (कॉन्ट्राइंडिकेशन))

When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (एज़ेटिमाइब लेबल, निषेध (कॉन्ट्राइंडिकेशन))

When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (एज़ेटिमाइब लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Transporters Use caution when concomitantly administering ALVAIZ and drugs that are substrates of OATP1B1 (e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP)… (एल्ट्रोम्बोपैग लेबल, दवाओं के इंटरैक्शन)

Bile Acid Sequestrants Clinical Impact: Concomitant cholestyramine administration decreased the mean exposure of total ezetimibe. (एज़ेटिमाइब लेबल, दवाओं के इंटरैक्शन)

Bile Acid Sequestrants Clinical Impact: Concomitant cholestyramine administration decreased the mean exposure of total ezetimibe. (एज़ेटिमाइब लेबल, दवाओं के इंटरैक्शन)

Bile Acid Sequestrants Clinical Impact: Concomitant cholestyramine administration decreased the mean exposure of total ezetimibe. (एज़ेटिमाइब लेबल, दवाओं के इंटरैक्शन)

Table 3: Clinically Important Drug Interactions with ZETIA Cyclosporine Clinical Impact: Concomitant use of ZETIA and cyclosporine increases ezetimibe and cyclosporine concentrations. (एज़ेटिमाइब लेबल, दवाओं के इंटरैक्शन)

All participants received simvastatin, 40 to 80 mg per day, plus ezetimibe 10 mg per day if needed, to maintain an LDL-C level of 40-80 mg/dL, and were randomized to receive niacin extended-release tablets 1500-2000 mg/day (n=1718) or matching placebo (IR Niacin, 100-150 mg, n=1696). (नियासिन लेबल, चेतावनियां और सावधानियां)